SCHEMBL540958

SCHEMBL540958

Cc1nc2ccccc2n1CCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.73
MEN1 O00255 4/20 0.68
KMT2A Q03164 4/20 0.68
LMNA P02545 4/20 0.65
RECQL P46063 1/20 0.65
MAPT P10636 1/20 0.65
POLB P06746 2/20 0.62
TP53 P04637 1/20 0.61
HTT P42858 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
KDM4E B2RXH2 1/20 0.61
PKM P14618 2/20 0.59
GALR3 O60755 2/20 0.58
NR2F2 P24468 2/20 0.58
RAB9A P51151 1/20 0.58
ALDH1A1 P00352 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6446137 0.87 LMNA (0.69) TNFLMNAMAPTTP53HTT
SCHEMBL3397633 0.85 LMNA (0.61) MEN1KMT2ALMNAMAPTTP53
SCHEMBL231295 0.84 TNF (1.00) TNFMEN1KMT2ALMNAMAPT
SCHEMBL6809570 0.84 MEN1 (0.53) TNFMEN1KMT2ALMNARECQL
SCHEMBL2330274 0.82 LMNA (0.69) TNFLMNATP53HTTPKM
SCHEMBL229041 0.82 POLB (0.67) TNFMEN1KMT2ALMNAMAPT
SCHEMBL29411911 0.81 ALDH1A1 (0.73) MEN1KMT2ALMNARECQLMAPT
SCHEMBL15314762 0.81 ALDH1A1 (0.73) MEN1KMT2ALMNARECQLMAPT
SCHEMBL5748764 0.81 MEN1 (1.00) MEN1KMT2ALMNAHTTKDM4E
SCHEMBL760728 0.81 PKM (0.60) TNFLMNAMAPTPOLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188282-B2 Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles SANOFI-AVENTIS (FR) 2012-05-29 US claimed
EP-2044033-B1 A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES SANOFI SA (FR) 2012-02-08 EP claimed
US-20100297038-A1 Benzimidazole Derivatives And Their Use As Cooling Agents GIVAUDAN S.A. (CH) 2010-11-25 US claimed
US-20090203912-A1 Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles SANOFI-AVENTIS (FR) 2009-08-13 US claimed
EP-1878724-A1 A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles sanofi-aventis (FR) 2008-01-16 EP claimed
CN-111978301-B Benzimidazole compound with endothelial lipase inhibition effect and application thereof 盐城师范学院 2022-08-02 CN disclosed
WO-2022057930-A1 BENZIMIDAZOLE COMPOUND HAVING ENDOTHELIAL LIPASE INHIBITION EFFECT, AND APPLICATION 盐城师范学院 2022-03-24 WO disclosed
CN-111978301-A Benzimidazole compound with endothelial lipase inhibition effect and application thereof 盐城师范学院 2020-11-24 CN disclosed
EP-2732819-A2 Compounds that enhance Atoh-1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2014-05-21 EP disclosed
US-8188282-B2 Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-8188282-B2 Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-8188282-B2 Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20090203912-A1 Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles SANOFI-AVENTIS (FR) 2009-08-13 US disclosed
US-20090203912-A1 Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles SANOFI-AVENTIS (FR) 2009-08-13 US disclosed
US-20090203912-A1 Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles SANOFI-AVENTIS (FR) 2009-08-13 US disclosed
WO-2009089641-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS COOLING AGENTS GIVAUDAN SA (CH) 2009-07-23 WO disclosed
EP-2044033-A1 A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES Sanofi-Aventis (FR) 2009-04-08 EP disclosed
WO-2008009348-A1 A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES SANOFI-AVENTIS (FR) 2008-01-24 WO disclosed
EP-1878724-A1 A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles sanofi-aventis (FR) 2008-01-16 EP disclosed
EP-1878724-A1 A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles sanofi-aventis (FR) 2008-01-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297038-A1 Benzimidazole Derivatives And Their Use As Cooling Agents OR10J3, H1-3, ORC3 TNF 4402/4885MEN1 1044/4885KMT2A 722/4885
US-20090203912-A1 Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles DDT, NIT2, PADI1 TNF 4798/4885MEN1 1756/4885KMT2A 778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.